New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Pfizer
UM Funding ID
FD04426
Sponsor
Pfizer
Category
International
Description
This competitive grant program seeks to support independent medical education addressing the new mechanisms in mCRPC including EZH2 inhibition and its possible role in prostate cancer and the continued unmet need for novel therapies in mCRPC.
Individual projects requesting up to $250,000 USD will be considered. Maximum project length is 18-24 months.
VPRI Contact
Heather Martin
Research Contracts Officerheatherdarlene [dot] .martin [at] @umanitoba [dot] .ca
Deadlines
| UM Internal Deadline (to ADR) | Sponsor Deadline | |
|---|---|---|
Application | 29-Sep-2026 | 21-Oct-2026 11:59 pm EST |
Important
The information in this directory is provided as a service to the University Community and anyone with legitimate business with the University. Use of this directory to prepare mass mailings is prohibited.